Reported 3 days ago
Akero Therapeutics saw its stock price double after revealing encouraging results from a trial of its liver disease treatment, efruxifermin (EFX), with 39% of patients showing reversal of cirrhosis over 96 weeks compared to 15% in the placebo group. CEO Dr. Andrew Cheng emphasized EFX's 'transformational potential' as the company progresses to Phase 3 trials.
Source: YAHOO